APA

Yang L., Qiu Q., Tang M., Wang F., Yi Y., Yi D., Yang Z., Zhu Z., Zheng S., Yang J., Pei H., Zheng L., Chen Y., Gou L., Luo L., Deng X., Ye H., Hu Y., Niu T. & Chen L. (20201026). Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Yang Linyu, Qiu Qiang, Tang Minghai, Wang Fang, Yi Yuyao, Yi Dongni, Yang Zhuang, Zhu Zejiang, Zheng Shoujun, Yang Jianhong, Pei Heying, Zheng Li, Chen Yong, Gou Liping, Luo Liya, Deng Xing, Ye Haoyu, Hu Yiguo, Niu Ting and Chen Lijuan. 20201026. Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Yang L., Qiu Q., Tang M., Wang F., Yi Y., Yi D., Yang Z., Zhu Z., Zheng S., Yang J., Pei H., Zheng L., Chen Y., Gou L., Luo L., Deng X., Ye H., Hu Y., Niu T. and Chen L. (20201026). Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Yang Linyu, Qiu Qiang, Tang Minghai, Wang Fang, Yi Yuyao, Yi Dongni, Yang Zhuang, Zhu Zejiang, Zheng Shoujun, Yang Jianhong, Pei Heying, Zheng Li, Chen Yong, Gou Liping, Luo Liya, Deng Xing, Ye Haoyu, Hu Yiguo, Niu Ting and Chen Lijuan. Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20201026.